If manipulation of Th17 is safe, it would be of interest to know whether augmenting the transcription factor RUNX1 for IL-17+IFNγ+ T cell phenotype induction will be beneficial in treating patients with cancer and autoimmune diseases. This evidence concerns the gene IFNG and autoimmune disease.